Cariprazine

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatigue, diabetes regardless of weight changes, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors. Cariprazine was approved for medical use in the US in September 2015. It was approved as a generic medication in 2022, but is covered by patents until 2029. Cariprazine was approved by the Therapeutic Goods Administration (TGA) for use in Australia in 2020. As of 2025, the cost of Cariprazine is generally around US$50, $25AUD on the PBS and £80.36 in the UK when on the National Health Service (NHS).